A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib

Phase 2

Bristol-Myers Squibb

Erlotinib Hydrochloride